Several in vitro studies suggested that HER2 overexpression can facilitate both the genomic and non-genomic action of ER and its coactivator AIB1 in breast cancer cells, leading to tamoxifen resistance (Chung et al. 2002, Shou et al. 2004). Here, NCOA3 is linked to breast cancer.